StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research note on Wednesday, August 7th.
Read Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Down 1.9 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Equities research analysts expect that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- What Investors Need to Know About Upcoming IPOs
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.